MedTrace Logo

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

NCT02914262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-03-16

No results posted yet for this study

Summary

This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.

Conditions

Interventions

DRUG

AKB-4924

Comparison of different dosages of AKB-4924

OTHER

Placebo

Placebo comparator

Sponsors & Collaborators

  • Aerpio Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael McDonnell, MD · Syneos Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2016-11-30
Completion
2017-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02914262 on ClinicalTrials.gov